Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

trastuzumab deruxtecan 4eribulin 3Capecitabine 3Trastuzumab 2Paclitaxel 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2telisotuzumab vedotin 1taxane 1pertuzumab 1pembrolizumab 1osimertinib 1olaparib 1margetuximab 1exemestane 1entrectinib 1encorafenib 1dacomitinib 1capmatinib 1binimetinib 1adagrasib 1abemaciclib 1Vinorelbine 1Vemurafenib 1Pemetrexed 1Imlunestrant 1Gefitinib 1Fulvestrant 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Neoplasm Metastasis × abemaciclib × Clear all
NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡